GSK fined £37m for ‘anti-competitive’ conduct

GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

GSK to widen access to medicines in world’s poorest countries

1 April 2016 Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

Big Pharma

GSK’s Seroxat pay-for-delay deals may restrict competition: AG

23 January 2020 GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union.

More on this story

Africa

GSK to widen access to medicines in world’s poorest countries

1 April 2016 Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

Big Pharma

GSK’s Seroxat pay-for-delay deals may restrict competition: AG

More on this story

Africa

GSK to widen access to medicines in world’s poorest countries

1 April 2016 Pharmaceutical company GSK has adopted a new approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.

Big Pharma

GSK’s Seroxat pay-for-delay deals may restrict competition: AG